Q3 revenue grew 3.72% year-over-year, but net profit fell 26.16% amid higher impairment losses and lower investment income. Major acquisition, share buybacks, and clinical trial progress marked the period, with strong cash flow from operations.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.